N-Boc-5-hydroxy-DL-norvaline | 85535-47-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Boc-5-hydroxy-DL-norvaline
• 英文别名: 5-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid
• CAS: 85535-47-3
• 化学式: C₁₀H₁₉NO₅
• 分子量: 233.265
• InChiKey: XKNSMPKNTBHIIH-UHFFFAOYSA-N

物化性质

• 沸点：
  411.2±40.0 °C(Predicted)
• 密度：
  1.175±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  95.9
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  溴甲苯 、 N-Boc-5-hydroxy-DL-norvaline 生成 N-(tert-butoxycarbonyl)-2-(3-hydroxypropyl)glycine benzyl ester
  参考文献：
  名称：

  [DE] VERBINDUNGEN ZUR MODULATION DES GLYKOLYSE-ENZYM-UND/ODER TRANSAMINASE-KOMPLEXES
  [EN] COMPOUNDS FOR MODULATING THE GLYCOLYSIS ENZYME COMPLEX AND/OR THE TRANSAMINASE COMPLEX
  [FR] COMPOSES DE MODULATION DU COMPLEXE DE L'ENZYME DE GLYCOLYSE ET/OU DE TRANSAMINASE

  摘要：

  公开号：

  WO2005054174A3
• 作为产物：
  描述：

  (S)-5-氨基-2-(Boc-氨基)-5-酮基戊酸 在 氨 、 sodium 作用下， 生成 N-Boc-5-hydroxy-DL-norvaline
  参考文献：
  名称：

  Sodium-liquid ammonia reduction of carboxamides to alcohols

  摘要：

  DOI：

  10.1021/jo00159a030

文献信息

• LYSINE ISOTOPOLOGUES, COMPOSITIONS COMPRISING THE SAME AND METHODS OF SYNTHESIS
  申请人：Cambridge Isotope Laboratories, Inc.

  公开号：US20160016890A1

  公开（公告）日：2016-01-21

  This invention relates to lysine isotopologues of Formulas I and 1-A, as described herein, and processes for synthesizing the same and derivatives and intermediates involved therein. In one aspect, described herein is a chemical compound comprising an isotopically labeled analog, i.e., an isotopologue of a standard or naturally occurring lysine. The lysine isotopologue is synthetically formed to have stable isotopes of elements incorporated at selected positions. As such, the lysine isotopologue has a molecular mass different from the mass of a standard or naturally occurring lysine.

  本发明涉及如本文所述的赖氨酸同位素异构体I和1-A的式子，以及合成这些同位素异构体及其衍生物和中间体的方法。在一个方面，本文描述了一种化学化合物，其包含一个同位素标记的类似物，即标准或天然存在的赖氨酸的同位素异构体。该赖氨酸同位素异构体是通过合成方法形成的，其中稳定元素同位素被整合到选定位置。因此，该赖氨酸同位素异构体的分子质量与标准或天然存在的赖氨酸的质量不同。
• [EN] MITOCHONDRIA-TARGETING PEPTIDES<br/>[FR] PEPTIDES CIBLANT LES MITOCHONDRIES
  申请人：STEALTH BIOTHERAPEUTICS CORP

  公开号：WO2019118878A1

  公开（公告）日：2019-06-20

  Disclosed are non-natural peptides useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.

  披露了用于治疗和预防缺血再灌注损伤（例如心脏缺血再灌注损伤）或心肌梗死的非天然肽。
• Dipeptide nitriles
  申请人：——

  公开号：US20040029814A1

  公开（公告）日：2004-02-12

  N-terminal substituted dipeptide nitrites as defined are useful as inhibitors of cysteine cathepsins, e.g. cathepsins B, K, L and S, and can be used for the treatment of cysteine cathepsin dependent diseases and conditions, including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, tumors (especially tumor invasion and tumor metastasis), coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization). Particular dipeptide nitrites are compounds of formula I, or physiologically-acceptable and -cleavable esters or a salts thereof 1 wherein: the symbols are as defined. In particular it has been found that by appropriate choice of groups R, R 2 , R 3 , R 4 , R 5 , X 1 , Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which selectively inhibit a particular cathepsin type or combination of cathepsin types.

  N-末端取代二肽硝酸盐可作为半胱氨酸蛋白酶的抑制剂，例如半胱氨酸蛋白酶B、K、L和S，并可用于治疗半胱氨酸蛋白酶依赖性疾病和病况，包括炎症、类风湿性关节炎、骨关节炎、骨质疏松症、肿瘤（尤其是肿瘤侵袭和转移）、冠心病、动脉粥样硬化（包括动脉粥样硬化斑块破裂和不稳定）。特定的二肽硝酸盐是化合物I的化合物，或其生理可接受和可分解的酯或盐。其中：符号如定义。特别是通过适当选择R、R2、R3、R4、R5、X1、Y和L的基团，可以改变化合物作为各种半胱氨酸蛋白酶类型的抑制剂的相对选择性，例如半胱氨酸蛋白酶B、K、L和S，以获得选择性抑制特定半胱氨酸蛋白酶类型或半胱氨酸蛋白酶类型组合的抑制剂。
• DIPEPTIDE NITRILES
  申请人：Altmann Eva

  公开号：US20080027060A1

  公开（公告）日：2008-01-31

  N-terminal substituted dipeptide nitriles as defined are useful as inhibitors of cysteine cathepsins, e.g. cathepsins B, K, L and S, and can be used for the treatment of cysteine cathepsin dependent diseases and conditions, including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, tumors (especially tumor invasion and tumor metastasis), coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization). Particular dipeptide nitriles are compounds of formula I, or physiologically-acceptable and -cleavable esters or a salts thereof wherein: the symbols are as defined. In particular it has been found that by appropriate choice of groups R, R 2 , R 3 , R 4 , R 5 , X 1 , Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which selectively inhibit a particular cathepsin type or combination of cathepsin types.

  N-末端取代二肽基腈可作为半胱氨酸蛋白酶的抑制剂，例如半胱氨酸蛋白酶B、K、L和S，并可用于治疗半胱氨酸蛋白酶依赖性疾病和病况，包括炎症、类风湿关节炎、骨关节炎、骨质疏松症、肿瘤（尤其是肿瘤侵袭和转移）、冠心病、动脉硬化（包括动脉粥样硬化斑块破裂和不稳定性）。特定的二肽基腈化合物为I式化合物，或其生理上可接受和可水解酯或其盐。其中：符号如定义。特别地，通过适当选择R、R2、R3、R4、R5、X1、Y和L基团，可以改变化合物作为各种半胱氨酸蛋白酶类型的抑制剂的相对选择性，例如获得选择性抑制特定半胱氨酸蛋白酶类型或半胱氨酸蛋白酶类型组合的抑制剂。
• [EN] RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN<br/>[FR] COMPOSÉS RADIOMARQUÉS CIBLANT L'ANTIGÈNE MEMBRANAIRE SPÉCIFIQUE DE LA PROSTATE
  申请人：UNIV BRITISH COLUMBIA

  公开号：WO2022126275A1

  公开（公告）日：2022-06-23

  The present invention relates to radiolabelled compounds for in vivo imaging or treatment of diseases or conditions characterized by expression of prostate-specific membrane antigen.

  本发明涉及放射性标记化合物，用于体内成像或治疗由前列腺特异性膜抗原表达所特征的疾病或病况。